ABUS 5.07 - here's the BNTX agreement with Genevant from 7/4/18
That deal was primarily for liver-targeting approach and oncology. However, it can easily be expanded to general infectious disease, where vaccines construct will come under LNP IP protection.
Market Data 
Markets 
AI
